Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis

Phase 2

Conditions: Gastric Cancer
Metastases to Perineum

Interventions: Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2011-11-11

Last Posted Date: 2012-12-07

Lead Sponsor: Peking University

Target Recruit Count: 20

Registration Number: NCT01471132

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Placebo
Drug: Pazopanib Hydrochloride

First Posted Date: 2011-11-10

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT01468909

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸
Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States

and more 139 locations

Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

Phase 3

Completed

Conditions: Genital Diseases, Female
Ovarian Diseases
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions: Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Other: specialized pathology review (Germany only)

First Posted Date: 2011-11-01

Last Posted Date: 2022-07-20

Lead Sponsor: AGO Study Group

Target Recruit Count: 927

Registration Number: NCT01462890

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

Phase 2

Terminated

Conditions: Gastro-oesophageal Junction Cancer
Gastric Cancer

Interventions: Drug: AZD4547
Drug: paclitaxel

First Posted Date: 2011-10-24

Last Posted Date: 2017-03-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 960

Registration Number: NCT01457846

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Effects of Paclitaxel on Intimal Hyperplasia

Not Applicable

Completed

Conditions: Peripheral Vascular Disease

Interventions: Drug: Paclitaxel

First Posted Date: 2011-10-19

Last Posted Date: 2016-05-24

Lead Sponsor: Patrick Kelly

Target Recruit Count: 50

Registration Number: NCT01454778

Locations: 🇺🇸
Sanford Vascular Associates, Sioux Falls, South Dakota, United States

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Erlotinib
Drug: Cisplatin
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2011-10-18

Last Posted Date: 2021-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 472

Registration Number: NCT01454102

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦
Local Institution, Toronto, Ontario, Canada

and more 7 locations

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: MM-121
Drug: Paclitaxel

First Posted Date: 2011-10-06

Last Posted Date: 2016-05-12

Lead Sponsor: Merrimack Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT01447706

Locations: 🇺🇸
Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸
Pinnacle Oncology, Scottsdale, Arizona, United States
🇺🇸
ProMedica Health System, Inc., Toledo, Ohio, United States

and more 7 locations

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

Phase 2

Completed

Conditions: Breast Neoplasms
Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Docetaxel
Drug: Abraxane
Drug: Ixabepilone

First Posted Date: 2011-10-04

Last Posted Date: 2023-01-23

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 38

Registration Number: NCT01446016

Locations: 🇺🇸
Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸
Houston Methodist Hospital Cancer Center, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital Willowbrook, Houston, Texas, United States

Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Phase 1

Completed

Conditions: Endometrial Mucinous Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrioid Adenocarcinoma
Recurrent Uterine Corpus Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IVB Uterine Corpus Cancer AJCC v7
Endometrial Adenocarcinoma

Interventions: Drug: Carboplatin
Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2011-09-27

Last Posted Date: 2018-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01440998

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Epirubicin
Drug: Paclitaxel
Drug: Capecitabine

First Posted Date: 2011-09-14

Last Posted Date: 2015-09-17

Lead Sponsor: Thomas Hatschek

Target Recruit Count: 304

Registration Number: NCT01433614

Locations: 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪
Kalmar Central Hospital, Kalmar, Sweden
🇸🇪
Helsingborg Gen. Hospital, Helsingborg, Sweden

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy